Published in Pharmacoeconomics on January 01, 1996
Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis. J Gen Intern Med (1993) 3.04
Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics (1993) 2.34
Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent. JAMA (1991) 1.71
Comparison of prevention strategies for neonatal group B streptococcal infection. A population-based economic analysis. JAMA (1993) 1.63
Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit Care Med (1993) 1.52
What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med (1987) 1.51
Roxithromycin versus cefaclor in lower respiratory tract infection: a general practice pharmacoeconomic study. Pharmacoeconomics (1993) 1.47
Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost--benefit analysis. J Pharm Sci (1979) 1.42
Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions. Pharmacoeconomics (1992) 1.12
Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals. Pharmacoeconomics (1992) 1.10
Cost-effectiveness opportunities for new antibiotics. Pharmacoeconomics (1994) 1.10
Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med (1989) 1.08
Pharmacoeconomics of intravenous drug administration. Pharmacoeconomics (1992) 0.99
Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. DICP (1991) 0.92
The role of insurance claims databases in drug therapy outcomes research. Pharmacoeconomics (1993) 0.89
Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA (1993) 0.88
Vaccination coverage of 2-year-old children--United States, 1993. MMWR Morb Mortal Wkly Rep (1994) 0.87
Prescription cost sharing: economic and health impacts, and implications for health policy. Pharmacoeconomics (1992) 0.84
Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections. Pharmacoeconomics (1993) 0.80
Review of cost-benefit analyses of influenza vaccine. Pharmacoeconomics (1992) 0.79
Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics (1992) 0.79
The economic impact of HA-1A (Centoxin) against endotoxin. Pharmacoeconomics (1992) 0.78
Evaluating the cost-effectiveness of treatment with third-generation cephalosporins. Diagn Microbiol Infect Dis (1992) 0.77
Cost analysis of imipenem-cilastatin versus clindamycin with tobramycin in the treatment of acute intra-abdominal infection. Pharmacoeconomics (1993) 0.77
A cost analysis of approved antiretroviral strategies in persons with advanced human immunodeficiency virus disease and zidovudine intolerance. J Acquir Immune Defic Syndr (1994) 0.77
Routine childhood immunisation: is it worth it? Pharmacoeconomics (1993) 0.77
Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother (1994) 0.77
Cost of treatment and prevention of Haemophilus influenzae type b disease. An international perspective. Pharmacoeconomics (1994) 0.77
Decision analysis in formulary decision making. Pharmacoeconomics (1993) 0.77
Pharmacoeconomics of immunisation: a review. Pharmacoeconomics (1993) 0.77
Rising research and development costs for new drugs in a cost containment environment. Pharmacoeconomics (1992) 0.77
Pharmacoeconomics of genetically engineered drugs. Pharmacoeconomics (1992) 0.76
Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. Pharmacoeconomics (1994) 0.76
Application of decision analysis in antibiotic formulary choices. J Pharm Technol (1994) 0.76
Organization of the sacral parasympathetic reflex pathways to the urinary bladder and large intestine. J Auton Nerv Syst (1981) 1.88
Parasympathetic preganglionic neurons in the sacral spinal cord. J Auton Nerv Syst (1982) 1.30
Changes in perceived heaviness and motor commands produced by cutaneous reflexes in man. J Physiol (1988) 1.07
Interaction of competitive antagonists: the anti-curare action of hexamethonium and other antagonists at the skeletal neuromuscular junction. Br J Pharmacol (1975) 0.99
Effects of hexamethonium and decamethonium on end-plate current parameters. Mol Pharmacol (1981) 0.99
Convergence of cutaneous and pelvic visceral nociceptive inputs onto primate spinothalamic neurons. Pain (1981) 0.95
Repeated exposure to sham testing procedures reduces reflex withdrawal and hot-plate latencies: attenuation of tonic descending inhibition? Neurosci Lett (1989) 0.91
Reimbursement of pharmaceuticals in New Zealand: comments on PHARMAC's processes. N Z Med J (2000) 0.89
Intracellular recording of after-discharge induced by veratrum alkaloids in the guinea-pig nodose ganglion. Brain Res (1975) 0.85
Intramuscular acupuncture-like electrical stimulation inhibits stretch reflexes in contralateral finger extensor muscles. Exp Neurol (1985) 0.81
Effects of 2,4-dinitrophenol amylobarbitone and certain other drugs on the rate of oxygen consumption and force of contraction of isolated curarized diaphragm muscle of the rat. Br J Pharmacol (1979) 0.79
Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia. Pharmacoeconomics (1992) 0.78
Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. Pharmacoeconomics (1992) 0.77
Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease. Pharmacoeconomics (1992) 0.77
Hypercapnia depresses nociception: endogenous opioids implicated. Brain Res (1990) 0.76
Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease. Pharmacoeconomics (1992) 0.76
Responses of primate spinothalamic neurons located in the sacral intermediomedial gray (Stilling's nucleus) to proprioceptive input from the tail. Brain Res (1982) 0.75
Trends in some cancer mortalities in New Zealand. N Z Med J (1972) 0.75
Contralateral intramuscular acupuncture-like electrical stimulation differentially changes the short-latency responses to muscle stretch. Exp Neurol (1987) 0.75